pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
Selinexor
Phase 2 · small molecule · Locally Advanced Unresectable or Metastatic Melanoma
Selinexor for Locally Advanced Unresectable or Metastatic Melanoma is a Phase 2 program (small_molecule) at Karyopharm Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code XPORT-MEL-033
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Karyopharm Therapeutics Inc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Locally Advanced Unresectable or Metastatic Melanoma
- Status
- terminated
- Trials
- 1